Earnest Partners LLC increased its holdings in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 0.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,292 shares of the medical equipment provider’s stock after purchasing an additional 53 shares during the quarter. Earnest Partners LLC’s holdings in Smith & Nephew SNATS were worth $1,056,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in SNN. Dalton Greiner Hartman Maher & Co. grew its position in shares of Smith & Nephew SNATS by 2,645.8% during the second quarter. Dalton Greiner Hartman Maher & Co. now owns 497,676 shares of the medical equipment provider’s stock worth $17,344,000 after purchasing an additional 479,551 shares in the last quarter. Citadel Advisors LLC boosted its stake in Smith & Nephew SNATS by 456.2% during the first quarter. Citadel Advisors LLC now owns 405,596 shares of the medical equipment provider’s stock valued at $12,545,000 after buying an additional 332,669 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Smith & Nephew SNATS by 95.0% during the second quarter. Goldman Sachs Group Inc. now owns 462,640 shares of the medical equipment provider’s stock valued at $16,123,000 after buying an additional 225,418 shares during the last quarter. Blue Jay Capital Management LLC bought a new position in Smith & Nephew SNATS during the second quarter valued at approximately $6,970,000. Finally, Bank of America Corp DE boosted its stake in Smith & Nephew SNATS by 10.9% during the first quarter. Bank of America Corp DE now owns 1,526,036 shares of the medical equipment provider’s stock valued at $47,200,000 after buying an additional 149,672 shares during the last quarter. Hedge funds and other institutional investors own 6.37% of the company’s stock.

Smith & Nephew SNATS, Inc. (NYSE SNN) opened at 37.56 on Wednesday. The company’s 50-day moving average price is $36.32 and its 200-day moving average price is $34.67. Smith & Nephew SNATS, Inc. has a 52 week low of $26.97 and a 52 week high of $40.43. The company has a market capitalization of $16.45 billion, a price-to-earnings ratio of 19.12 and a beta of 0.74.

The business also recently declared a semiannual dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th will be given a $0.246 dividend. The ex-dividend date is Thursday, October 5th. This represents a dividend yield of 1.37%.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/11/smith-nephew-snats-inc-snn-shares-bought-by-earnest-partners-llc.html.

A number of equities analysts recently commented on SNN shares. BidaskClub lowered Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Zacks Investment Research raised Smith & Nephew SNATS from a “hold” rating to a “buy” rating and set a $41.00 price target for the company in a research note on Wednesday, September 20th. Finally, Canaccord Genuity started coverage on Smith & Nephew SNATS in a research note on Wednesday. They set a “buy” rating and a $42.00 price target for the company. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $41.50.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Institutional Ownership by Quarter for Smith & Nephew SNATS (NYSE:SNN)

Receive News & Stock Ratings for Smith & Nephew SNATS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS Inc. and related stocks with our FREE daily email newsletter.